RecruitingNCT07035886
A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
Post-Marketing Surveillance (Usage Results Study) of Fruzaqla Capsule (Fruquintinib) for the Approved Indications in South Korea
Sponsor
Takeda
Enrollment
600 participants
Start Date
Sep 29, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Age greater than or equal to (\>=)18 years.
- Participants who are initiate treatment or will be treated with Fruzaqla according to the approved label of South Korea.
- Participant voluntarily consent to participate in the study.
Exclusion Criteria3
- Participants for whom Fruzaqla is contraindicated or those with risks that should avoid starting Fruzaqla, as per the product label.
- Participants actively participating in other interventional clinical trial(s) on mCRC treatments.
- Pregnant or breastfeeding women.
Interventions
OTHERNo intervention
As this is an observational study, no intervention will be administered.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07035886
Related Trials
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
Camera Capsule Endoscopy in the Routine Diagnostic Pathway for Colorectal Diseases
NCT064755601 location
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT070717141 location
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location